Showing: 10 - 12 of 99 RESULTS
Announcements Niemann-Pick Type C News Research News

IntraBio files New Drug Application for N-acetyl-L-leucine (IB1001) for the treatment of NPC

IntraBio Inc. is pleased to share that the New Drug Application (NDA) for N-acetyl-L-leucine (IB1001) for the treatment of Niemann-Pick disease type C (NPC) was submitted to the US Food and DrugAdministration (FDA) in January 2024. The FDA has a 60-day filing review period to determine whetherthe NDA is complete and accepted for review. With …

Announcements Niemann-Pick Type C News Research News

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the FDA

December 27, 2023 at 7:30 AM EST CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease therapeutics company, today announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type C (NPC) to the U.S. Food and Drug Administration (FDA) on December 22, 2023. Based …